Effect of Tofacitinib in treatment of Covid-19
Phase 2
Recruiting
- Conditions
- Coronavirus.COVID19, virus identifiedU07. 1
- Registration Number
- IRCT20200426047212N2
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
informed written desire and consent to participate in the study
Age 18 years or older
Hospitalization
Severe disease
Positive polymerase chain reaction (PCR) test
Lung involvement based on CT scan
Exclusion Criteria
Death of the patient
Physician's diagnosis of not participating in the study
History of thrombosis or current thrombosis
Suppression of the known immune system
Pregnancy and lactation
Use of angiotensin converting inhibitors
Severe renal, hepatic, respiratory and cardiovascular insufficiency
Consumption of cytotoxic drugs
Transfer to another hospital
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method